Industry Connections
This content and the opinions expressed herein are those of the supporter or industry event provider and not those of the San Antonio Breast Cancer Symposium (SABCS®).
The San Antonio Breast Cancer Symposium (SABCS®) has no editorial oversight in the creation of content provided or supported by industry.
Provided Content
-
VISIT GENENTECH BOOTH #143 for the INAVO120 PFS and OS Data
INDUSTRY PROVIDED CONTENT Visit Genentech Booth #143 for the INAVO120 PFS and OS Data Explore the primary and exploratory PFS analyses, and the final OS analysis for the Itovebi® (inavolisib) […]
Supported Content
-
Advancing Therapeutic Options for Patients in TNBC
Immunotherapy, PARP inhibitors, and antibody-drug conjugates have revolutionized the therapeutic landscape for triple-negative breast cancer (TNBC). With new compounds and combinations under investigation, lessons learned in metastatic TNBC are becoming equally valuable in early-stage disease, as well as in other subsets of breast cancer. Learn from Sonya Reid, MD, MPH, and Manali Bhave, MD, about the current landscape and how it may evolve. Kayla Freeman, DNP, reviews best practices for prophylactic and reactive management of common side effects with antibody-drug conjugates of interest.